

Patient Information Fax completed form, insurance information and clinical documentation to 515.559.2495.

Patient Name: _____ **DOB:** _____ **Phone:** _____

Patient Status: New to Therapy Continuing Therapy **Next Treatment Date:** _____

Medical Information

Diagnosis: Multiple sclerosis

Type: Relapsing-Remitting Primary-Progressive Secondary-Progressive Clinically Isolated

ICD-10 Code: G35

Patient weight: _____ lbs. (required) **Allergies:** _____

Therapy Order

Ocrevus:

 Loading Dose: 300 mg IV at 0 and 2 weeks, then 600 mg IV every 6 months x1 year

 600 mg IV every 6 months x1 year

Protocol premedication orders: Solu-Medrol 100 mg IV and Benadryl 25 mg PO 30 minutes before infusion

Additional premedication orders: _____

Lab Orders: _____ **Lab Frequency:** _____

Required labs to be drawn by: Hy-Vee Health Referring Provider

Other orders: _____

Anaphylactic reaction orders:

- Epinephrine (based on patient weight)
 - >30kg (>66lbs): EpiPen 0.3 mg or compounded syringe IM or Sub-Q; may repeat in 5-10 minutes x1
 - 15-30kg (33-66lbs): EpiPen Jr. 0.15 mg or compounded syringe IM or Sub-Q; may repeat in 5-10 minutes x1
- Diphenhydramine: Administer 25-50 mg orally **OR** IV (adult)
- Famotidine 20 mg IV as needed (adult)
- NS 0.9% 500 mL IV bolus as needed (adult)
- Refer to physician order or institutional protocol for pediatric dosing

Flush orders: NS 1-20 mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN

Provider Information

By signing this form and utilizing our services, you are authorizing *Hy-Vee Health* and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

Provider Name: _____ **Signature:** _____ **Date:** _____

Provider NPI: _____ **Phone:** _____ **Fax:** _____ **Contact Person:** _____

Opt out of Hy-Vee Health selecting site of care (if checked, please list site of care): _____

Service Areas

Des Moines, IA West Des Moines, IA Chicago, IL Omaha, NE Buffalo, NY Dallas, TX

Phoenix, AZ Other _____

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.

Patient Information

Patient Name: _____ DOB: _____

Required Documentation for Referral Processing & Insurance Approval

Include signed and completed order (MD/prescriber to complete page 1)

Include patient demographic information and insurance information

Include patient's medication list

Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits or contraindications to therapy

Expanded Disability Status Scale (EDSS) score: _____

Include labs and/or test results to support diagnosis

MRI

If applicable – Last known biological therapy: _____ and last date received: _____. If patient is switching to biologic therapies, please perform a washout period of _____ weeks prior to starting Ocrevus.

Other medical necessity: _____

Required Prescreening

Hepatitis B screening test completed. This includes Hepatitis B antigen and Hepatitis B core antibody total (not IgM) – attach results

Positive Negative

*If Hepatitis B results are positive, please provide documentation of treatment or medical clearance.

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.